Oramed Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Oramed Pharmaceuticals has a total shareholder equity of $202.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $220.5M and $18.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$134.69m |
| Equity | US$202.33m |
| Total liabilities | US$18.16m |
| Total assets | US$220.49m |
Recent financial health updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 13
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
May 31Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Recent updates
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
Dec 24Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential
Nov 21Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 13We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
May 31Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Financial Position Analysis
Short Term Liabilities: ORMP's short term assets ($136.1M) exceed its short term liabilities ($6.1M).
Long Term Liabilities: ORMP's short term assets ($136.1M) exceed its long term liabilities ($12.0M).
Debt to Equity History and Analysis
Debt Level: ORMP is debt free.
Reducing Debt: ORMP had no debt 5 years ago.
Debt Coverage: ORMP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ORMP has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 08:52 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oramed Pharmaceuticals Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| Robert LeBoyer | Ladenburg Thalmann & Company |